Promyelocytic leukemia protein is required for gain of function by mutant p53.

Mutations in the p53 tumor suppressor are the most common genetic events in human cancer. These mutations not only result in a loss of wild-type p53 activity, but can also lead to a gain of new oncogenic properties. Understanding how these gained functions are regulated is in its infancy. In this study, we show that the promyelocytic leukemia (PML) protein is an important regulator of mutant p53. We show that PML interacts with mutant p53. Importantly, PML enhances the transcriptional activity of mutant p53. Unexpectedly, PML is required for the proliferation and colony formation of cancer cells bearing mutant p53. Down-regulation of PML expression inhibits the growth of mutant p53-expressing cancer cells, predominantly by promoting cell cycle arrest. Our results suggest that the tumor suppression function of PML depends on the status of p53. In the context of mutant p53, PML enhances its cancer-promoting activities.

[1]  E. Appella,et al.  PML enhances the regulation of p53 by CK1 in response to DNA damage , 2008, Oncogene.

[2]  T. Iwakuma,et al.  The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. , 2008, Genes & development.

[3]  E. White,et al.  Does control of mutant p53 by Mdm2 complicate cancer therapy? , 2008, Genes & development.

[4]  D. Schiff,et al.  PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. , 2008, Cancer research.

[5]  Erik Meulmeester,et al.  p53: a guide to apoptosis. , 2008, Current cancer drug targets.

[6]  G. Blandino,et al.  Mutant p53 proteins: Between loss and gain of function , 2007, Head & neck.

[7]  G. Blandino,et al.  Mutant p53: an oncogenic transcription factor , 2007, Oncogene.

[8]  T. Iwakuma,et al.  Crippling p53 activities via knock-in mutations in mouse models , 2007, Oncogene.

[9]  Giulia Piaggio,et al.  Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. , 2006, Cancer cell.

[10]  T. Stamminger,et al.  Evidence for a Role of the Cellular ND10 Protein PML in Mediating Intrinsic Immunity against Human Cytomegalovirus Infections , 2006, Journal of Virology.

[11]  R. Everett,et al.  PML Contributes to a Cellular Mechanism of Repression of Herpes Simplex Virus Type 1 Infection That Is Inactivated by ICP0 , 2006, Journal of Virology.

[12]  N. Gueven,et al.  The complexity of p53 stabilization and activation , 2006, Cell Death and Differentiation.

[13]  Jason A. Koutcher,et al.  Identification of a tumour suppressor network opposing nuclear Akt function , 2006, Nature.

[14]  G. Blandino,et al.  Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression , 2006, Oncogene.

[15]  R. Mantovani,et al.  Direct p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G2/M Promoters , 2005, Molecular and Cellular Biology.

[16]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[17]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[18]  J. Manfredi,et al.  DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. , 2004, Molecular cell.

[19]  C. Gespach,et al.  Nuclear bodies and compartments: functional roles and cellular signalling in health and disease. , 2004, Cellular signalling.

[20]  Zigang Dong,et al.  Post-translational modification of p53 in tumorigenesis , 2004, Nature Reviews Cancer.

[21]  P. Pandolfi,et al.  Loss of the tumor suppressor PML in human cancers of multiple histologic origins. , 2004, Journal of the National Cancer Institute.

[22]  P. Pandolfi,et al.  Promyelocytic Leukemia Protein 4 Induces Apoptosis by Inhibition of Survivin Expression* , 2004, Journal of Biological Chemistry.

[23]  E. Appella,et al.  Phosphorylation Site Interdependence of Human p53 Post-translational Modifications in Response to Stress* , 2003, Journal of Biological Chemistry.

[24]  Pier Paolo Pandolfi,et al.  The Promyelocytic Leukemia Protein Protects p53 from Mdm2-mediated Inhibition and Degradation* , 2003, Journal of Biological Chemistry.

[25]  P. Pelicci,et al.  The PML gene is not involved in the regulation of MHC class I expression in human cell lines. , 2003, Blood.

[26]  A. Dejean,et al.  Deconstructing PML‐induced premature senescence , 2002, The EMBO journal.

[27]  R. Bernards,et al.  A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.

[28]  H. Drexler,et al.  Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines. , 2002, Leukemia research.

[29]  Pier Paolo Pandolfi,et al.  The Role of PML in Tumor Suppression , 2002, Cell.

[30]  G. Zambetti,et al.  The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. , 2001, Gene.

[31]  R. Mantovani,et al.  NF-Y Mediates the Transcriptional Inhibition of thecyclin B1, cyclin B2, and cdc25CPromoters upon Induced G2 Arrest* , 2001, The Journal of Biological Chemistry.

[32]  V. Rotter,et al.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. , 2000, Cancer research.

[33]  P. Pandolfi,et al.  Regulation of p53 activity in nuclear bodies by a specific PML isoform , 2000, The EMBO journal.

[34]  Ailan Guo,et al.  The function of PML in p53-dependent apoptosis , 2000, Nature Cell Biology.

[35]  Giulia Piaggio,et al.  The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated , 1999, Oncogene.

[36]  A. Levine,et al.  Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy , 1999, Oncogene.

[37]  M. Koken,et al.  PML induces a novel caspase-independent death process , 1998, Nature Genetics.

[38]  P. Pandolfi,et al.  Role of PML in cell growth and the retinoic acid pathway. , 1998, Science.

[39]  P. Pelicci,et al.  Analysis of p53 gene mutations in acute myeloid leukemia , 1994, American journal of hematology.

[40]  P. Pelicci,et al.  Frequency of RAS and p53 mutations in acute promyelocytic leukemias. , 1993, Leukemia & lymphoma.

[41]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[42]  V. Rotter,et al.  Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. , 1991, Cancer research.

[43]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.